HRP20192230T1 - Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita - Google Patents
Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita Download PDFInfo
- Publication number
- HRP20192230T1 HRP20192230T1 HRP20192230TT HRP20192230T HRP20192230T1 HR P20192230 T1 HRP20192230 T1 HR P20192230T1 HR P20192230T T HRP20192230T T HR P20192230TT HR P20192230 T HRP20192230 T HR P20192230T HR P20192230 T1 HRP20192230 T1 HR P20192230T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmacological agent
- tat
- peptide
- intended
- mast cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18594309P | 2009-06-10 | 2009-06-10 | |
| EP10786870.5A EP2440231B1 (en) | 2009-06-10 | 2010-06-10 | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
| PCT/US2010/038226 WO2010144742A2 (en) | 2009-06-10 | 2010-06-10 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192230T1 true HRP20192230T1 (hr) | 2020-03-20 |
Family
ID=43309471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192230TT HRP20192230T1 (hr) | 2009-06-10 | 2010-06-10 | Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8933013B2 (enExample) |
| EP (2) | EP3682895A1 (enExample) |
| JP (5) | JP5886192B2 (enExample) |
| AU (1) | AU2010259986B2 (enExample) |
| CA (2) | CA2765171C (enExample) |
| CY (1) | CY1122584T1 (enExample) |
| DK (1) | DK2440231T3 (enExample) |
| ES (1) | ES2765281T3 (enExample) |
| HR (1) | HRP20192230T1 (enExample) |
| HU (1) | HUE046640T2 (enExample) |
| LT (1) | LT2440231T (enExample) |
| PL (1) | PL2440231T3 (enExample) |
| PT (1) | PT2440231T (enExample) |
| SI (1) | SI2440231T1 (enExample) |
| SM (1) | SMT202000056T1 (enExample) |
| WO (1) | WO2010144742A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| PL2320927T3 (pl) * | 2008-07-09 | 2016-02-29 | Univ Copenhagen | Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD |
| PT2440231T (pt) * | 2009-06-10 | 2020-01-08 | Nono Inc | Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos |
| SI3354657T1 (sl) | 2009-09-22 | 2022-05-31 | Medicago Inc. | Postopek za pripravo iz rastlin izpeljanih beljakovin |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| HRP20220519T1 (hr) | 2011-06-24 | 2022-05-27 | Nono Inc. | Kombinacijska terapija ishemije |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| TR201905787T4 (tr) * | 2012-11-28 | 2019-05-21 | Nono Inc | Liyofilize TAT-NR2B9C formülasyonu. |
| WO2016172219A1 (en) * | 2015-04-24 | 2016-10-27 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation |
| WO2017115853A1 (ja) | 2015-12-28 | 2017-07-06 | 出光興産株式会社 | ペプチドタグおよびそれを含むタグ付加タンパク質 |
| KR102403089B1 (ko) * | 2017-07-05 | 2022-06-02 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도 |
| CN111417394B (zh) | 2017-10-19 | 2023-11-07 | 帝人制药株式会社 | 苯并咪唑衍生物及其用途 |
| AU2021206472A1 (en) * | 2020-01-09 | 2022-08-18 | Nono Inc. | Plasmin-resistant peptides for treating stroke and related conditions |
| EP4274596A4 (en) | 2021-01-08 | 2024-12-25 | NoNO Inc. | Plasmin-resistant peptides for improved therapeutic index |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| CA2354644A1 (en) | 1998-12-11 | 2000-06-15 | Biomira, Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US20040226056A1 (en) | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| DE60026313D1 (de) | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| WO2001013957A2 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| WO2003024389A2 (en) | 2001-07-30 | 2003-03-27 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| CA2505479A1 (en) * | 2002-11-14 | 2004-06-03 | Arbor Vita Corporation | Molecular interactions in neurons |
| WO2004071531A1 (en) | 2003-02-13 | 2004-08-26 | Licentia Oy | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| US20050209141A1 (en) * | 2003-10-17 | 2005-09-22 | Silver Randi B | Mast cell-derived renin |
| US20050256065A1 (en) * | 2004-01-26 | 2005-11-17 | Permasight | Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents |
| US7151084B2 (en) | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| KR101384572B1 (ko) | 2005-12-30 | 2014-04-24 | 아버 비타 코포레이션 | Ｐｄｚ 상호작용의 소형 분자 억제제 |
| CA2657665C (en) * | 2006-07-11 | 2015-06-02 | Arbor Vita Corporation | Method and compositions for treating stroke with fever |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| ES2446292T3 (es) | 2007-03-02 | 2014-03-07 | Nono Inc. | Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N |
| WO2009006611A1 (en) | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| DK2178549T3 (en) | 2007-07-26 | 2017-01-09 | Revance Therapeutics Inc | Antimicrobial peptide AND COMPOSITIONS THEREOF |
| ES2328776B1 (es) | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| PL2320927T3 (pl) | 2008-07-09 | 2016-02-29 | Univ Copenhagen | Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD |
| PT2440231T (pt) | 2009-06-10 | 2020-01-08 | Nono Inc | Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos |
-
2010
- 2010-06-10 PT PT107868705T patent/PT2440231T/pt unknown
- 2010-06-10 HR HRP20192230TT patent/HRP20192230T1/hr unknown
- 2010-06-10 AU AU2010259986A patent/AU2010259986B2/en not_active Ceased
- 2010-06-10 ES ES10786870T patent/ES2765281T3/es active Active
- 2010-06-10 CA CA2765171A patent/CA2765171C/en active Active
- 2010-06-10 JP JP2012515161A patent/JP5886192B2/ja not_active Expired - Fee Related
- 2010-06-10 DK DK10786870.5T patent/DK2440231T3/da active
- 2010-06-10 SM SM20200056T patent/SMT202000056T1/it unknown
- 2010-06-10 PL PL10786870T patent/PL2440231T3/pl unknown
- 2010-06-10 EP EP19210675.5A patent/EP3682895A1/en not_active Withdrawn
- 2010-06-10 HU HUE10786870A patent/HUE046640T2/hu unknown
- 2010-06-10 WO PCT/US2010/038226 patent/WO2010144742A2/en not_active Ceased
- 2010-06-10 US US13/377,519 patent/US8933013B2/en active Active
- 2010-06-10 SI SI201031965T patent/SI2440231T1/sl unknown
- 2010-06-10 CA CA3018494A patent/CA3018494C/en active Active
- 2010-06-10 EP EP10786870.5A patent/EP2440231B1/en active Active
- 2010-06-10 LT LTEP10786870.5T patent/LT2440231T/lt unknown
-
2014
- 2014-12-29 US US14/585,028 patent/US9433685B2/en not_active Expired - Fee Related
-
2015
- 2015-07-03 JP JP2015134712A patent/JP6238934B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-24 US US15/245,693 patent/US10046060B2/en active Active
-
2017
- 2017-09-19 JP JP2017179192A patent/JP6775478B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-12 US US16/034,235 patent/US20190038760A1/en not_active Abandoned
-
2019
- 2019-12-23 CY CY20191101350T patent/CY1122584T1/el unknown
-
2020
- 2020-04-17 JP JP2020074428A patent/JP7209364B2/ja active Active
-
2022
- 2022-10-25 JP JP2022170797A patent/JP2023017813A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530060A5 (enExample) | ||
| ES2685505T3 (es) | Inhibidor de cinasas basado en péptidos de permeación celular | |
| ES2879550T3 (es) | Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares. | |
| CA2829101C (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| IL273913B2 (en) | Tripeptidyl peptidase-1 preparations and methods for treating neuronal ceroid liposuction disease | |
| JP2013543492A5 (enExample) | ||
| RU2013127565A (ru) | Ингибиторы апоптоза и их применение | |
| ES2765281T3 (es) | Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio | |
| BRPI0914504B1 (pt) | uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv | |
| JP7071287B2 (ja) | 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 | |
| ES2523858T3 (es) | Fragmentos de VIP y composiciones de los mismos | |
| EP3820470B1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension | |
| CN113735938B (zh) | 一种神经保护多肽化合物及其应用 | |
| CN105451756A (zh) | 在治疗马凡氏综合征及其相关病症中的血管紧张素肽 | |
| JP2009500045A5 (enExample) | ||
| Sharif-Alhoseini et al. | Underlying causes of paresthesia | |
| CN111032055A (zh) | 使用胰高血糖素样肽2的下尿路上皮的治疗 | |
| Wang et al. | Loganin epigenetically rescues mitochondrial complex III dysfunction via DNMT1-UQCRC1 demethylation to halt cardiac remodeling after myocardial infarction | |
| WO2020055226A1 (es) | Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona | |
| Gheorghiade et al. | Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output | |
| CA3088576C (en) | COMPOSITION INTENDED FOR THE TREATMENT OF A PATIENT SUFFERING FROM ULCERATIVE COLITIS AND USE OF THE COMPOSITION AS A MEDICINE | |
| JP2014512369A5 (enExample) | ||
| ES2617235T3 (es) | Uso de pidotimod para tratar psoriasis | |
| JP5477794B2 (ja) | エンドキニンｃ／ｄ由来のペプチド | |
| Zhang et al. | Efficacy and safety of combination of magnesium sulfate, phentolamine and nifedipine in treatment of patients with hypertensive disorder complicating pregnancy |